GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VYNE Therapeutics Inc (NAS:VYNE) » Definitions » EPS without NRI

VYNE Therapeutics (VYNE Therapeutics) EPS without NRI : $-6.74 (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is VYNE Therapeutics EPS without NRI?

VYNE Therapeutics's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.44. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.74.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 65.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 59.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for VYNE Therapeutics's EPS without NRI or its related term are showing as below:

VYNE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -81.1   Med: 34.55   Max: 65.2
Current: 65.2

During the past 9 years, VYNE Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 65.20% per year. The lowest was -81.10% per year. And the median was 34.55% per year.

VYNE's 3-Year EPS without NRI Growth Rate is ranked better than
95.93% of 1302 companies
in the Biotechnology industry
Industry Median: 5.3 vs VYNE: 65.20

VYNE Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.44. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.28.

VYNE Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.44. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.28.


VYNE Therapeutics EPS without NRI Historical Data

The historical data trend for VYNE Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VYNE Therapeutics EPS without NRI Chart

VYNE Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -222.48 -64.70 -15.46 -10.65 -2.72

VYNE Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.32 -1.74 -2.81 -1.75 -0.44

Competitive Comparison of VYNE Therapeutics's EPS without NRI

For the Biotechnology subindustry, VYNE Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VYNE Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where VYNE Therapeutics's PE Ratio without NRI falls into.



VYNE Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VYNE Therapeutics  (NAS:VYNE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


VYNE Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of VYNE Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


VYNE Therapeutics (VYNE Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
685 Route 202/206 North, Suite 301, Bridgewater, NJ, USA, 08807
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Executives
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Mutya Harsch officer: Chief Legal Officer and GC C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Tyler Zeronda officer: Interim CFO C/O VYNE THERAPEUTICS, 520 U.S. HIGHWAY 22, SUITE 204, BRIDGEWATER NJ 08807
Andrew Saik officer: Chief Financial Officer 640 LEE ROAD, CHESTERBROOK PA 19087
Rex Bright director 5641 LAKE VISTA DRIVE, BONSALL CA 92003
Iain Stuart officer: Chief Scientific Officer C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
David Domzalski director, officer: President and CEO C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Matthew T. Wiley officer: Chief Commercial Officer C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Anthony D Bruno director C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Stanley Hirsch director C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Ilan Hadar officer: CFO and Country Manager C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003